Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced hair thinning due to a testosterone spike and used a minoxidil solution and topical finasteride gel. After four months, the gel caused side effects without improving hair thinning, leading to questions about continuing or adjusting the treatment.

The user is concerned about low DHT levels due to using saw palmetto in Foligain supplements and is considering trying finasteride. They seek advice on whether finasteride will also lower DHT and how to manage DHT levels.

Despite using treatments like Dutasteride, Minoxidil, RU58841, and GHK-Cu injections, the individual continues to experience aggressive hair thinning and is seeking a specialist for further help. Suggestions include trying finasteride, dermarolling, or another hair transplant.

The conversation is about a female experiencing hair loss and seeking advice on why it's difficult to regrow hair. Specific treatments like Minoxidil, finasteride, or RU58841 are not mentioned.

The user underwent a hair transplant with 2800 grafts and used a topical treatment containing minoxidil. They also had scalp micropigmentation (SMP) to enhance the results, which cost $15,000 for the surgery and $1,500 for SMP sessions.

The user is happy with their hair transplant results after 6 months, using minoxidil and PRP sessions, but is unsure about not addressing the temples. Others reassure them that the hairline looks natural and age-appropriate, though some suggest considering finasteride or dutasteride for maintenance.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.

A user shared their 7-month hairline recovery using 1 mg finasteride and 5 mg minoxidil daily. They experienced significant hair growth, including unwanted facial hair, and discussed potential side effects and dosage adjustments with others.

The user has been on finasteride for 7 years and had a hair transplant, but is experiencing hair thinning and itchiness, particularly on one side, leading to concerns about male pattern baldness or other health issues. Despite having a full head of hair, the user is considering shaving it due to mental health struggles and is advised to consult a therapist and consider other treatments like minoxidil or dutasteride.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

A user shared a 5-month update on their hair transplant, praising the natural results and the surgeon in Patna, India. They mentioned using 2000 grafts at a cost of 90,000 INR and discussed the importance of taking finasteride or dutasteride to maintain the transplanted hair.

Hair loss may be linked to blood flow and inflammation, with treatments like Minoxidil, finasteride, and quercetin being discussed. The conversation also mentions the role of 5AR enzyme distribution in hair follicles.

The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.

A user shared their experience with a 7600 graft hair transplant using scalp, beard, and chest hair over three procedures, expressing satisfaction with the results despite mixed feedback. They also used finasteride to thicken hair and considered scalp micropigmentation for further improvement.

The conversation discusses the potential availability of GT20029 for hair loss treatment, with one user noting promising Phase 1 results and inquiring about gray market access. Another user humorously suggests it will take 50 years to become available.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

The user is experiencing hairline thinning despite using finasteride, minoxidil (solution and foam), dermastamping, and tretinoin. They suspect minoxidil or tretinoin might be causing the issue but are unsure.

A 25-year-old experiencing hair thinning all over the body and head, despite using minoxidil and having low vitamin D levels, is advised to seek a second opinion from a dermatologist specializing in hair loss. The likely diagnosis is diffuse alopecia areata, which may require treatment with a JAK inhibitor.

A humorous discussion about random, long hairs appearing on the body, with no connection to hair loss treatments like Minoxidil, finasteride, or RU58841. Participants share personal anecdotes about these unusual hairs.

The conversation discusses a user's plan to inject NAD+ and GHK-Cu into their scalp to improve hair health, with concerns raised about the risks of infection and necrosis. Alternatives like finasteride, dutasteride, microneedling, oral minoxidil, and scalp massages are suggested.

The user is experiencing breast tenderness and lumps after three weeks on 0.5 mg oral finasteride, a common side effect. They also report mild brain fog and fatigue but are less concerned about these symptoms.

An 18-year-old male is experiencing hair loss and is using topical minoxidil and oral finasteride. He is concerned about continued shedding, mild sexual side effects, and whether to adjust his finasteride dosage.

A user shared a 10-month update on their hair loss treatment, including a hair transplant of 2300 grafts and 7.5 months of using a topical minoxidil/finasteride solution and ketoconazole shampoo. They expressed regret for not starting the medications sooner and reported side effects like heart palpitations, which improved after cutting out caffeine.

Verteporfin is being explored for hair regeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hair regeneration.

The user, who experienced hair loss at the temples due to psoriasis at 17, is now 21 and considering treatment options. They are inquiring about using minoxidil once a day, whether non-AGA hair loss will persist after stopping minoxidil, and if alternative remedies like Detumescence therapy, rosemary and peppermint oils, and microneedling could be sufficient.

The conversation discusses using microneedling with copper peptides, specifically GHK-Cu, for hair loss treatment. Some users combine it with minoxidil and topical finasteride, applying peptides either topically or through injection.

The user plans to start a 12-month finasteride treatment to combat aggressive hair loss, with regular monitoring of thyroid levels, testosterone, DHT, liver enzymes, PSA, and iron levels. They seek advice on additional monitoring and aim to balance results with minimal side effects.

Some people don't see results with FDA-approved hair loss treatments like finasteride or minoxidil due to underlying issues. The video suggests addressing these issues, especially if there are atypical symptoms or other health conditions.